GoAI
Get started
COMPASS Pathways plc logo

COMPASS Pathways plc

CMPS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.33

−$0.49 · -3.55%

Aug 21, 4:00 PM ET

CMPS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

38

Expensive

Momentum

71

Gaining

Sentiment

67

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Industry
Biotechnology
Sector
Healthcare
Headquarters
GB
CEO
Kabir Kumar Nath
Listed since
Sep 18, 2020
Employees
156

Market position

Day range

Current $13.33

52-week range

Current $13.33

Open
$13.945
Previous close
$13.82
Volume
2.08M
0.48× average
Average volume
4.39M
Average daily volume
Market cap
1.8B USD
Beta
2.53
Market reference 1
50-day average
$12.8008
+4.13% above average
200-day average
$8.7505
+52.33% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-2.39×
P/B (TTM)
14.77×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.65×

Financial statements

Income trends

Operating income

−179.04M USD-0.47%

Net income

−287.86M USD-85.57%
Income trends across reported periods−50.13M USD−136.58M USD−223.03M USD−309.47M USDOperating income, FY2021: −83.22M USDOperating income, FY2022: −110.4M USDOperating income, FY2023: −136.92M USDOperating income, FY2024: −178.21M USDOperating income, FY2025: −179.04M USDNet income, FY2021: −71.74M USDNet income, FY2022: −91.51M USDNet income, FY2023: −118.46M USDNet income, FY2024: −155.12M USDNet income, FY2025: −287.86M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −83.22M USD. Operating income FY2022 −110.4M USD. Operating income FY2023 −136.92M USD. Operating income FY2024 −178.21M USD. Operating income FY2025 −179.04M USD. Net income FY2021 −71.74M USD. Net income FY2022 −91.51M USD. Net income FY2023 −118.46M USD. Net income FY2024 −155.12M USD. Net income FY2025 −287.86M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development118.44M USD119.04M USD87.52M USD65.05M USD44.03M USD
Selling, general, and administrative60.6M USD59.17M USD49.4M USD45.35M USD39.19M USD
Operating expenses179.04M USD178.21M USD136.92M USD110.4M USD83.22M USD
Interest income7.18M USD8.27M USD4.62M USD——
Interest expense4.52M USD4.48M USD2.2M USD——
Depreciation and amortization216K USD233K USD242K USD330K USD175K USD
Operating income−179.04M USD−178.21M USD−136.92M USD−110.4M USD−83.22M USD
Net income−287.86M USD−155.12M USD−118.46M USD−91.51M USD−71.74M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-32.02%
11 comparable reports
Latest EPS result
-0.36
Estimate -0.46 · Beat by 21.74%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-0.65-1.09-1.54Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.63, estimate -0.62, surprise -1.61%, Miss. Q2 2025, reported May 8, 2025: actual -0.24, estimate -0.47, surprise +48.94%, Beat. Q3 2025, reported Jul 31, 2025: actual -0.38, estimate -0.37, surprise -2.70%, Miss. Q4 2025, reported Nov 4, 2025: actual -1.44, estimate -0.4, surprise -260.00%, Miss. Q1 2026, reported Mar 24, 2026: actual -1, estimate -0.41, surprise -143.90%, Miss. Q2 2026, reported May 13, 2026: actual -0.3, estimate -0.45, surprise +33.33%, Beat. Q3 2026, reported Aug 5, 2026: actual -0.36, estimate -0.46, surprise +21.74%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.363, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.63

39.76% upside
Past 12 months12-month forecastHigh $25.00Average $18.63Low $13.00

Rating distribution

15 ratings
Strong buy00%
Buy15100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
B. Riley SecuritiesmaintainBuy
StifelmaintainBuy
OppenheimermaintainOutperform

CMPS news

marketbeat.com

Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances

Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with…

Read source
businesswire.com

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that…

Read source
businesswire.com

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it…

Read source
businesswire.com

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that…

Read source
seekingalpha.com

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Compass Pathways Q2 Earnings Call Highlights

Compass Pathways NASDAQ: CMPS said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III…

Read source

CMPS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CMPS

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
61.94M
Weight
2.99%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$49.45+3.80%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
11.23M
Weight
0.11%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
AdvisorShares Psychedelics ETF logoAdvisorShares Psychedelics ETFPSIL
Market value
6.06M
Weight
10.50%
AUM
57.72M USD
Expense ratio
1.84%
Price / 1D
$25.86-0.35%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
2.11M
Weight
0.89%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
1.52M
Weight
1.79%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
1.13M
Weight
0.12%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%
AdvisorShares Dorsey Wright logoAdvisorShares Dorsey WrightAADR
Market value
789.76K
Weight
2.02%
AUM
39.12M USD
Expense ratio
1.17%
Price / 1D
$84.1177+1.10%
ROBO Global Healthcare Technology and Innovation ETF logoROBO Global Healthcare Technology and Innovation ETFHTEC
Market value
778.87K
Weight
1.01%
AUM
74.46M USD
Expense ratio
0.80%
Price / 1D
$43.58+2.40%

Continue in GoAI

Research CMPS

research.disclaimer